14 Hospital Physician Board Review Manual www.turner-white.com
BRCA: the tubal fimbria emerges as an origin for pelvic
serous cancer. Clin Med Res 2007;5:35–44.
5. Kurman RJ. Origin and molecular pathogenesis of ovarian
high-grade serous carcinoma, Ann Oncol 2013;24 Suppl
6. Kim J, Coffey DM, Creighton CJ et al, High-grade serous
ovarian cancer arises from fallopian tube in a mouse model.
Proc Natl Acad Sci U S A 2012;109:3921–6.
7. Boyd J. Specific keynote: hereditary ovarian cancer: what
we know. Gynecol Oncol 2003;88( 1 Pt 2):S8–10.
8. Hartge P, Whittemore AS, Itnyre J, et al. Rates and risks of
ovarian cancer in subgroups of white women in the United
States. The Collaborative Ovarian Cancer Group. Obstet
Gynecol 1994:84:760– 4.
9. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:
10. Whittemore AS. Characteristics relating to ovarian cancer
risk: implications for prevention and detection. Gynecol
Oncol 1994;55( 3 Pt 2):S15–9.
11. Shu XO, Brinton LA, Gao YT, et al. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res
12. Negri E, Franceschi S, Tzonou A, et al. Pooled analysis of 3
European case-control studies: I. Reproductive factors and
risk of epithelial ovarian cancer. Int J Cancer 1991;49:50– 6.
13. Rodriguez C, Patel AV, Calle EE, et al. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460– 5.
14. Cramer DW, Liberman RE, Titus-Ernstoff L, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer
15. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study
of the Centers for Disease Control and the National Institute
of Child Health and Human Development. N Engl J Med
16. Hankinson SE, Colditz GA, Hunter DJ, et al. A quantitative
assessment of oral contraceptive use and risk of ovarian
cancer. Obstet Gynecol 1992;80:708–14.
17. Titus-Ernstoff L, Perez K, Cramer DW, et al. Menstrual and
reproductive factors in relation to ovarian cancer risk. Br J
18. Ness RB, Grisso JA, Cottreau C, et al. Factors related to
inflammation of the ovarian epithelium and risk of ovarian
cancer. Epidemiology 2000;11:111–7.
19. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation,
hysterectomy, and risk of ovarian cancer. A prospective
study. JAMA 1993;270:2813–8.
20. Asante A, Leonard PH, Weaver AL, et al. Fertility drug use
and the risk of ovarian tumors in infertile women: a case-control study. Fertil Steril 2013;99:2031–6.
21. Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in
women treated with ovarian stimulating drugs for infertility.
Cochrane Database Syst Rev 2013;13:CD008215.
22. Riman T, Dickman PW, Nilsson S, et al. Risk factors for
invasive epithelial ovarian cancer: results from a Swedish
case-control study. Am J Epidemiol 2002;156:363–72.
23. Prat J. New insights into ovarian cancer pathology. Ann
Oncol 2012;23(suppl 10):x111–17.
24. Kerlikowske K, Brown JS, Grady DG. Should women with familial ovarian cancer undergo prophylactic oophorectomy?
Obstet Gynecol 1992;80:700– 7.
25. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2
mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807–16.
26. NCCN Clinical Practice Guidelines in Oncology: Ovarian
Cancer. Including fallopian tube cancer and primary peritoneal cancer. Version 1.2015. http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed March 5,
27. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer
associated with specific mutations of BRCA1 and BRCA2
among Ashkenazi Jews. N Engl J Med 1997;336:1401–8.
28. Anglian Breast Cancer Study Group. Prevalence and
penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer
29. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy
and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA
30. Tonin P, Weber B, Offit K, et al. Frequency of recurrent
BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast
cancer families. Nat Med 1996;2:1179–83.
31. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of
BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002;20:463–6.
32. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA
33. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line
mutations of BRCA1. N Engl J Med 1996;335:1413–6.
34. Goodheart M J, Rose SL, Hattermann-Zogg M, et al.
BRCA2 alteration is important in clear cell carcinoma of the
ovary. Clin Genet 2009;76:161–7.
35. Aarnio M, Mecklin JP, Aaltonen LA, et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer
(HNPCC) syndrome. Int J Cancer 1995; 64:430– 3.
36. Loveday C, Turnbull C, Hughes D, et al. Germline mutations in Rad51D confer susceptibility to ovarian cancer, Nat